Marshall Wace, LLP
- SEC CIK
- 0001318757
- Latest filing
- Aug 13, 2026
HALO holding history
Halozyme Therapeutics, Inc. in every 13F filed by Marshall Wace, LLP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
HALO overviewAll 13F holders of HALOFull Q2 2026 holdings
- Shares (Q2 2026)
- 188,354
- Value
- $14.7M
- % of portfolio
- <0.1%
- Quarters held
- 13
- Since Q2 2022
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 188,354 | $14.7M | <0.1% | +67,348+55.7% | Added | Holders |
| Q1 2026 | 121,006 | $7.82M | <0.1% | −376,194−75.7% | Reduced | Holders |
| Q4 2025 | 497,200 | $33.5M | <0.1% | +103,445+26.3% | Added | Holders |
| Q3 2025 | 393,755 | $28.9M | <0.1% | +4,624+1.2% | Added | Holders |
| Q2 2025 | 389,131 | $20.2M | <0.1% | −74,477−16.1% | Reduced | Holders |
| Q1 2025 | 463,608 | $29.6M | <0.1% | +459,182+10,374.6% | Added | Holders |
| Q4 2024 | 4,426 | $211.6K | <0.1% | +4,426 | New | Holders |
| Q2 2024 | 0 | $0 | 0.0% | −75,533−100.0% | Sold out | Holders |
| Q1 2024 | 75,533 | $3.07M | <0.1% | −570,635−88.3% | Reduced | Holders |
| Q4 2023 | 646,168 | $23.9M | <0.1% | −2,078,643−76.3% | Reduced | Holders |
| Q3 2023 | 2,724,811 | $104.1M | 0.2% | +401,288+17.3% | Added | Holders |
| Q2 2023 | 2,323,523 | $83.8M | 0.2% | +1,433,856+161.2% | Added | Holders |
| Q1 2023 | 889,667 | $34.0M | 0.1% | +889,667 | New | Holders |
| Q3 2022 | 0 | $0 | 0.0% | −110,861−100.0% | Sold out | Holders |
| Q2 2022 | 110,861 | $4.88M | <0.1% | +110,861 | New | Holders |